healthcare

healthcare Articles

NewLink Genetics shares jumped on Wednesday after the firm announced that the FDA has accepted Merck’s Biologics License Application and granted priority review for the investigational Ebola...
Aimmune shares dipped on Monday after the FDA's Allergenic Products Advisory Committee voted to support the use of AR101 (Palforzia) in children and teens with peanut allergy.
Alder Bio shares skyrocketed on Monday after the firm announced that Lundbeck would be acquiring it. The transaction is valued at up to $1.95 billion and is expected to close in the fourth quarter of...
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.
Ardelyx shares dropped on Friday after the firm announced that the FDA has approved its treatment of irritable bowel syndrome with constipation in adults.
Life science technology company 10X Genomics entered the market with a bang on Thursday in its initial public offering.
Adverum Bio shares dropped sharply on Thursday after the firm announced data from its Optic Phase 1 clinical trial in wet age-related macular degeneration.
The August 30 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks increased.
The August 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The August 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
After Lexicon Pharmaceuticals announced the termination of its alliance with Sanofi, its shares rallied on Wednesday.
Xeris Pharmaceuticals shares were halted briefly on Tuesday after the firm announced that it has received regulatory approval from the FDA for Gvoke, its treatment of severe hypoglycemia in pediatric...
Intra-Cellular Therapies shares dipped on Tuesday after the firm released a disappointing update from the FDA concerning its treatment for schizophrenia.
Amgen shares dropped on Monday after the firm released additional data from its early-stage lung cancer study. Specifically this data is coming from the ongoing Phase 1 study evaluating AMG 510 in...
Eli Lilly shares dipped on Monday after the firm announced results from its midstage clinical trial for the treatment of lung cancer.